Avalo Therapeutics, Inc. 2026: Revenue ($36.94M), Net income ($36.36M), EPS ($0.83) — 10-Q Summary
Avalo Therapeutics, Inc. reported a comprehensive loss of ($36.94M) and a net loss of ($36.36M) for the quarter ended 2026, with diluted loss per share at ($0.83). The company achieved positive Phase 2 results for abdakibart in hidradenitis suppurativa and completed a $405M equity …